Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disea...(ard-looking statements include statement...),Health

Date:8/19/2008

ard-looking statements include statements about the Karolinska Institute's and the SMI's plans for a prime-boost HIV vaccine clinical trial, the potential effect of the company's Vaxfectin(R) adjuvant and Biojector(R) 2000 needle-free injection system on vaccine performance, and the design and potential benefits of HIV DNA vaccines generally. Risks and uncertainties include whether Vical, the Karolinska Institute the SMI or others will continue development of the HIV vaccine; whether the SMI will sponsor and the Karolinska Institute will complete preclinical testing and conduct a Phase 1 trial using a Vaxfectin(R)-formulated DNA prime-MVA boost vaccination regimen; whether such trial, if conducted, will use the Biojector(R) 2000 needle-free injection system to deliver the DNA priming vaccine; whether Vaxfectin(R) will optimize the DNA vaccine priming of immune responses against the specific HIV vaccine targets and increase the performance of, or eliminate the need for, the MVA vaccine boost; whether Vaxfectin(R)-formulated DNA priming vaccines will increase the breadth and magnitude of immune responses to the prime-boost regimen; whether the prime- boost vaccine regimen will be effective in protecting humans against HIV infection or disease; whether the HIV vaccine will achieve the safety and immunogenicity endpoints in the Phase 1 trial; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward- looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website:

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
3. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
8. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type